Literature DB >> 19258594

BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells.

Lingchen Fu1, Yen-Chiu Lin-Lee, Lan V Pham, Archito T Tamayo, Linda C Yoshimura, Richard J Ford.   

Abstract

BLyS and its major receptor BAFF-R have been shown to be critical for development and homeostasis of normal B lymphocytes, and for cell growth and survival of neoplastic B lymphocytes, but the biologic mechanisms of this ligand/receptor-derived intracellular signaling pathway(s) have not been completely defined. We have discovered that the BAFF-R protein was present in the cell nucleus, in addition to its integral presence in the plasma membrane and cytoplasm, in both normal and neoplastic B cells. BAFF-R interacted with histone H3 and IKKbeta in the cell nucleus, enhancing histone H3 phosphorylation through IKKbeta. Nuclear BAFF-R was also associated with NF-kappaB/c-Rel and bound to NF-kappaB targeted promoters including BLyS, CD154, Bcl-xL, IL-8, and Bfl-1/A1, promoting the transcription of these genes. These observations suggested that in addition to activating NF-kappaB pathways in the plasma membrane, BAFF-R also promotes normal B-cell and B-cell non-Hodgkin lymphoma (NHL-B) survival and proliferation by functioning as a transcriptional regulator through a chromatin remodeling mechanism(s) and NF-kappaB association. Our studies provide an expanded conceptual view of the BAFF-R signaling, which should contribute a better understanding of the physiologic mechanisms involved in normal B-cell survival and growth, as well as in the pathophysiology of aggressive B-cell malignancies and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258594      PMCID: PMC2680367          DOI: 10.1182/blood-2008-10-183467

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Collecting and harvesting biological data: the GPCRDB and NucleaRDB information systems.

Authors:  F Horn; G Vriend; F E Cohen
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators.

Authors:  Benjamin L Hsu; Susan M Harless; R Coleman Lindsley; David M Hilbert; Michael P Cancro
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

Review 3.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

4.  Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1.

Authors:  Xiangao Huang; Maurizio Di Liberto; Adam F Cunningham; Lin Kang; Shuhua Cheng; Scott Ely; Hsiou-chi Liou; Ian C M Maclennan; Selina Chen-Kiang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-10       Impact factor: 11.205

5.  NF-kappa B-dependent assembly of an enhanceosome-like complex on the promoter region of apoptosis inhibitor Bfl-1/A1.

Authors:  Leonard C Edelstein; Lynn Lagos; Matthew Simmons; Hemamalini Tirumalai; Céline Gélinas
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

6.  Nuclear localization of EGF receptor and its potential new role as a transcription factor.

Authors:  S Y Lin; K Makino; W Xia; A Matin; Y Wen; K Y Kwong; L Bourguignon; M C Hung
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

7.  The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.

Authors:  Mi-Ae Lyu; Lawrence H Cheung; Walter N Hittelman; John W Marks; Ricardo C T Aguiar; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2007-01-31       Impact factor: 6.261

8.  NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells.

Authors:  Eunice N Hatada; Richard K G Do; Amos Orlofsky; Hsiou-Chi Liou; Michael Prystowsky; Ian C M MacLennan; Jorge Caamano; Selina Chen-Kiang
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

9.  BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells.

Authors:  Estefania Claudio; Keith Brown; Sun Park; Hongshan Wang; Ulrich Siebenlist
Journal:  Nat Immunol       Date:  2002-09-23       Impact factor: 25.606

10.  IkappaB kinase signaling is essential for maintenance of mature B cells.

Authors:  Manolis Pasparakis; Marc Schmidt-Supprian; Klaus Rajewsky
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more
  43 in total

1.  Regulation of B cell activating factor (BAFF) receptor expression by NF-ΚB signaling in rheumatoid arthritis B cells.

Authors:  Yun Ju Woo; Bo Young Yoon; Joo Yeon Jhun; Hye Jwa Oh; Se Won Min; Mi La Cho; Sung Hwan Park; Ho Youn Kim; Jun Ki Min
Journal:  Exp Mol Med       Date:  2011-06-30       Impact factor: 8.718

Review 2.  New molecular targets in mantle cell lymphoma.

Authors:  Samir Parekh; Marc A Weniger; Adrian Wiestner
Journal:  Semin Cancer Biol       Date:  2011-09-18       Impact factor: 15.707

Review 3.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

4.  Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.

Authors:  Shannon L Haley; Evgeni P Tzvetkov; Samantha Meuwissen; Joseph R Plummer; James P McGettigan
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

5.  CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Authors:  Hong Qin; Zhenyuan Dong; Xiuli Wang; Wesley A Cheng; Feng Wen; Weili Xue; Han Sun; Miriam Walter; Guowei Wei; D Lynne Smith; Xiuhua Sun; Fan Fei; Jianming Xie; Theano I Panagopoulou; Chun-Wei Chen; Joo Y Song; Ibrahim Aldoss; Clarisse Kayembe; Luisa Sarno; Markus Müschen; Giorgio G Inghirami; Stephen J Forman; Larry W Kwak
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

6.  Release the ink4a/arf growth suppression by "u" and "me"?

Authors:  Shuo Qie; Nianli Sang
Journal:  Cell Cycle       Date:  2011-01-15       Impact factor: 4.534

Review 7.  B cells in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Bruce R Blazar; Corey Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-12       Impact factor: 5.742

8.  Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.

Authors:  Daniel J Medina; Lauri Goodell; John Glod; Céline Gélinas; Arnold B Rabson; Roger K Strair
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

9.  IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DeltaNp73alpha phosphorylation and stabilization.

Authors:  Rosita Accardi; Mariafrancesca Scalise; Tarik Gheit; Ishraq Hussain; Jiping Yue; Christine Carreira; Agnese Collino; Cesare Indiveri; Lutz Gissmann; Bakary S Sylla; Massimo Tommasino
Journal:  Mol Cell Biol       Date:  2011-04-11       Impact factor: 4.272

10.  Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.

Authors:  Qingyu Zeng; Zhihan Zhou; Shanshan Qin; Yajie Yao; Jiamin Qin; Hai Zhang; Ruijie Zhang; Chong Xu; Shuangquan Zhang; Shile Huang; Long Chen
Journal:  Cell Calcium       Date:  2020-02-07       Impact factor: 6.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.